🏛️ Verified NIH Record • Updated 2025-04-14
A Dose Escalation Study Evaluating CPI-818 in Relapsed/Refractory T-Cell Lymphoma (NCT03952078)
A Phase 1/1b Dose-Escalation Trial Evaluating CPI-818, an Oral Interleukin-2-Inducible T-Cell Kinase Inhibitor, in Subjects With Relapsed/Refractory T-Cell Lymphoma
🔵 Active, Not Recruiting Phase1 💊 Investigational Drug / Biologic Sponsor: Corvus Pharmaceuticals, Inc.
🩺 Plain-English Summary (8th-Grade Level)
This is a Phase 1/1b, open-label, first in human study of CPI-818, an oral interleukin-2-inducible tyrosine kinase (ITK) inhibitor for the treatment of relapsed/refractory (R/R) T-cell lymphoma.. This trial will study the safety, tolerability, and anti-tumor activity of CPI-818 as a single drug.
Who can join: Review the eligibility criteria below.
Location: Stanford University — Palo Alto, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (22 Sites)
- Stanford University — Palo Alto, California
- University of Michigan — Ann Arbor, Michigan
- Washington University — St Louis, Missouri
- Hackensack University Medical Center — Hackensack, New Jersey
- Ohio State University — Columbus, Ohio
- University of Pittsburgh — Pittsburgh, Pennsylvania
- Concord Repatriation General Hospital — Concord, New South Wales
- Liverpool Hospital — Liverpool, New South Wales
- Royal Adelaide Hospital — Adelaide, South Australia
- Epworth Healthcare — Melbourne, Victoria
- Beijing Friendship Hospital — Beijing, Beijing Municipality
- Beijing Boren Hospital — Beijing, Beijing Municipality
- Beijing Cancer Hospital — Beijing, Beijing Municipality
- Shanghai East Hospital — Pudong, Shanghai Municipality
- Henan Cancer Hospital — Henan, Zhengzhou
- Seoul National University Hospital — Seoul, Gyeonggido
- Asan Medical Center — Seoul, Gyeonggido
- Samsung Medical Center — Seoul, Gyeonggido
- Seoul St. Mary's Hospital — Seoul, Gyeonggido
- Inje University Busan-Paik Hospital — Busan,
- Pusan National University Hospital — Busan,
- Gachon University — Incheon,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in T-cell Lymphoma
- A Study of Enasidenib in People With T-Cell Lymphoma — Basking Ridge, New Jersey
- CD4CAR for CD4+ Leukemia and Lymphoma — Miami, Florida
- Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory T-cell Lymphoma — New Haven, Connecticut
- A Registry for People With T-cell Lymphoma — Duarte, California
- Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma — Columbus, Ohio
Explore by condition: All T-cell Lymphoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.